Loading…
Theriva Biologics, Inc. is projected to decline to $0.2341 by 2027, a -3% move from its current price of $0.2419. TOVX is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/12/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Jul 13 | $0.2309 | $0.2419 | $0.2534 | +0.01% |
| Jul 14 | $0.2266 | $0.2419 | $0.2584 | +0.02% |
| Jul 15 | $0.2233 | $0.242 | $0.2622 | +0.03% |
| Jul 16 | $0.2205 | $0.242 | $0.2655 | +0.03% |
| Jul 17 | $0.2181 | $0.242 | $0.2685 | +0.04% |
| Jul 18 | $0.216 | $0.242 | $0.2712 | +0.05% |
| Jul 19 | $0.2141 | $0.242 | $0.2737 | +0.06% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $0.2141 | $0.242 | $0.2737 | +0.06% |
| Week 2 | $0.2036 | $0.2422 | $0.2881 | +0.12% |
| Week 3 | $0.1959 | $0.2423 | $0.2998 | +0.18% |
| Week 4 | $0.1897 | $0.2425 | $0.31 | +0.24% |
| Week 5 | $0.1844 | $0.2426 | $0.3193 | +0.30% |
| Week 6 | $0.1797 | $0.2428 | $0.328 | +0.36% |
| Week 7 | $0.1755 | $0.2429 | $0.3362 | +0.42% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Theriva Biologics, Inc. is a clinical-stage healthcare company focused on developing therapeutics to treat cancer and related diseases in the United States. Its lead product candidate, VCN-01 (zabilugene almadenorepvec), is a clinical-stage oncolytic human adenovirus that is in Phase 1 clinical trials and in the Phase 2 VIRAGE trial for patients with pancreatic cancer, head and neck squamous cell carcinoma, ovarian cancer, colorectal cancer, and retinoblastoma.
The company also develops VCN-11 for treating solid tumors; SYN-004 (ribaxamase), an oral capsule prophylactic therapy that is in Phase 1b/2a clinical trials for the prevention of acute graft-versus-host-disease in allogeneic hematopoietic cell transplant; and SYN-020, a recombinant oral formulation of the enzyme intestinal alkaline phosphatase for multiple gastrointestinal and metabolic indications. In addition, it develops clinical-stage products such as SYN-006 to prevent acute graft-versus-host-disease, Clostridioides difficile infection, and microbiome damage in patients treated with carbapenem antibiotics; and SYN-007 for preventing antibiotic associated diarrhea with oral ß-lactam antibiotics. Theriva Biologics, Inc.
is headquartered in Rockville, Maryland.
Theriva Biologics, Inc. trades under the symbol TOVX. Its current price is $0.2511 and its market capitalization is $11.52M. It ranks 5111. The near‑term price picture reflects a defined 30‑day window and a clear support/resistance framework, with a long‑term forecast that shows potential upside amid notable volatility.
A major floor 25.6% below — a decisive break under it would weaken the trend.
The nearest floor, 4.9% below — buyers have tended to step in here.
The nearest ceiling, 28.2% above — a clean break opens room to run.
A major ceiling 69.5% above — clearing it would confirm fresh momentum.
Key TOVX support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of TOVX market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $0.24 | Buy | $0.2399 | Buy |
| MA 10 | $0.246 | Sell | $0.2444 | Sell |
| MA 20 | $0.257 | Sell | $0.2535 | Sell |
| MA 50 | $0.2894 | Sell | $0.2679 | Sell |
| MA 100 | $0.2603 | Sell | $0.2721 | Sell |
| MA 200 | $0.2673 | Sell | $0.4179 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 41.82 | Neutral |
| Stoch RSI (14) | 54.41 | Neutral |
| CCI (20) | -67.46 | Neutral |
| Williams %R (14) | -66.67 | Info |
| MACD (12,26,9) | -0.00 | Sell |
| ROC (12) | -4.00 | Sell |
| Bollinger %B (20,2) | 0.30 | Neutral |
| Stochastic %K (14) | 33.33 | Neutral |
| TRIX (15) | -0.68 | Sell |
| Awesome (5,34) | -0.03 | Sell |
| Ultimate (7,14,28) | 37.34 | Neutral |
| Momentum (10) | 0.00 | Neutral |
| Aroon Osc (25) | -72.00 | Sell |
| Hull MA (9) | 0.23 | Buy |
| ADX (14) | 15.50 | Neutral |
| ATR (14) | 0.01 | Info |
Sentiment is NEUTRAL. The RSI(14) is 40, and the stock trades around the SMA(50) of $0.3074 and the SMA(200) of $0.2787. The security sits near a support level of $0.24 and a resistance level of $0.36. The 30‑day range runs from $0.1632 to $0.3863.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $0.18 | $0.2419 | $0.3028 | 0% | Neutral | |
| $0.1743 | $0.2341 | $0.3388 | -3% | Neutral | |
| $0.1409 | $0.1993 | $0.3053 | -18% | Bearish | |
| $0.1405 | $0.2075 | $0.3322 | -14% | Neutral | |
| $0.1654 | $0.254 | $0.4216 | +5% | Neutral | |
| $0.1667 | $0.2655 | $0.4549 | +10% | Neutral | |
| $0.1932 | $0.3185 | $0.5612 | +32% | Bullish | |
| $0.1991 | $0.3392 | $0.6128 | +40% | Bullish | |
| $0.1633 | $0.2871 | $0.5307 | +19% | Neutral | |
| $0.163 | $0.2956 | $0.5581 | +22% | Bullish | |
| $0.208 | $0.4368 | $0.8998 | +81% | Bullish | |
| $0.2722 | $0.6049 | $1.39 | +150% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $0.18 | $0.2419 | $0.2843 | +0.00% |
| August 2026 | $0.1936 | $0.2328 | $0.2906 | -3.74% |
| September 2026 | $0.2002 | $0.2438 | $0.3099 | +4.69% |
| October 2026 | $0.1953 | $0.2403 | $0.3102 | -1.42% |
| November 2026 | $0.1834 | $0.2276 | $0.2976 | -5.29% |
| December 2026 | $0.1829 | $0.229 | $0.3028 | +0.59% |
Click any year to see its month-by-month TOVX forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
Expect TOVX to range from $0.18 to $0.3028 through 2026. The $0.2419 average target implies a 0% move from current prices. Price action looks broadly range-bound.
The TOVX price prediction for 2027 points to an average of $0.2341 (low $0.1743, high $0.3388) — a potential decline of -3% on today's $0.2419. A consolidation phase looks the most probable path here.
In 2028, TOVX is projected to trade between $0.1409 and $0.3053, averaging $0.1993 — a potential decline of -18% from today's $0.2419. That is -15% versus the projected 2027 average. A cyclical pullback looks likely — prices rarely move in a straight line.
Theriva Biologics, Inc.'s 2029 outlook centres on $0.2075, within a $0.1405 to $0.3322 range. That is up +4% on the projected 2028 average. That marks a -14% change versus current levels. A consolidation phase looks the most probable path here.
By 2030, TOVX could reach as high as $0.4216, with a base case around $0.254 and support toward $0.1654 — roughly +5% from $0.2419. Price action looks broadly range-bound.
Expect TOVX to range from $0.1667 to $0.4549 through 2031. The $0.2655 average target implies a +10% move from current prices. That is up +5% on the projected 2030 average. A consolidation phase looks the most probable path here.
The TOVX price prediction for 2032 points to an average of $0.3185 (low $0.1932, high $0.5612) — a potential gain of +32% on today's $0.2419. Momentum favours further upside here.
In 2033, TOVX is projected to trade between $0.1991 and $0.6128, averaging $0.3392 — a potential gain of +40% from today's $0.2419. That is up +6% on the projected 2032 average. Buyers look set to stay in control over this stretch.
Theriva Biologics, Inc.'s 2034 outlook centres on $0.2871, within a $0.1633 to $0.5307 range. That is -15% versus the projected 2033 average. That marks a +19% change versus current levels. Price action looks broadly range-bound.
By 2035, TOVX could reach as high as $0.5581, with a base case around $0.2956 and support toward $0.163 — roughly +22% from $0.2419. Buyers look set to stay in control over this stretch.
Expect TOVX to range from $0.208 to $0.8998 through 2040. The $0.4368 average target implies a +81% move from current prices. That is up +48% on the projected 2035 average. Momentum favours further upside here.
The TOVX price prediction for 2050 points to an average of $0.6049 (low $0.2722, high $1.39) — a potential gain of +150% on today's $0.2419. Buyers look set to stay in control over this stretch.
Investing $1,000 in TOVX today (≈ 4,133.939644 TOVX) could be worth
$2,500.51
+$1,500.51 (+150%) by 2050 · US Dollar
Based on the average projected TOVX price of $0.6 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in TOVXwould be worth at today's price.
$1,000 invested in TOVX on Jul 10, 2025 (≈ 2,127.65958 TOVX) would be worth
$514.68
-$485.32 (-48.5%) today · 0.51× · US Dollar
Based on a TOVX entry price of $0.47 vs. today's $0.2419.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $0.25 | $967.6 | -3.2% |
| 1 month ago | $0.24 | $1,007.92 | +0.8% |
| 3 months ago | $0.23 | $1,051.74 | +5.2% |
| 6 months ago | $0.22 | $1,099.55 | +10.0% |
| 1 year ago | $0.47 | $514.68 | -48.5% |
| All time (5.0y) ago | $137.5 | $1.76 | -99.8% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our TOVX forecast.
Our base-case forecast reaches $0.48 around 2050.
Implied market cap at $0.48: $22.03M
The multi‑year forecast shows upside potential, with 2030 avg $0.2559 (ROI 1.9%), 2040 avg $0.4727 (ROI 88.3%), and 2050 avg $0.636 (ROI 153.3%). Earlier years include mixed results, such as 2027 avg $0.2263 (ROI −9.9%), 2028 avg $0.2037 (ROI −18.9%), and 2029 avg $0.2156 (ROI −14.1%). The forecast also highlights bullish years in 2032 with avg $0.3546 (ROI 41.2%) and 2033 with avg $0.3547 (ROI 41.3%).
By 2035, the avg is $0.3114 with ROI 24%, and by 2040 the avg rises toward $0.4727, with a max around $1.04 and ROI 88.3%; by 2050 the avg reaches $0.636 with a max of $1.46 and ROI 153.3%. These figures are estimates and not guarantees; actual results may differ and depend on future developments and market conditions.
Tap a question to reveal the answer.
Avg $0.2559 with ROI 1.9% (min $0.1577, max $0.4451).
Forecasts show mixed results: 2030 avg $0.2559 (ROI 1.9%), 2040 avg $0.4727 (ROI 88.3%), and 2050 avg $0.636 (ROI 153.3%). Earlier years include negative ROI years, so outcomes are uncertain.
Yes—the max forecast by 2050 is $1.46.
Current price is $0.2511 and market cap is $11.52M; it is ranked 5111.
Sentiment NEUTRAL; RSI(14) 40; SMA(50) $0.3074; SMA(200) $0.2787; 30-day range $0.1632-$0.3863; support $0.24; resistance $0.36.
Theriva Biologics, Inc. Community Discussion
0Share your Theriva Biologics, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.